Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 4 | 2021 | 686 | 0.810 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2021 | 82 | 0.790 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 193 | 0.740 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 202 | 0.730 |
Why?
|
| Gene Amplification | 1 | 2021 | 731 | 0.640 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 2796 | 0.630 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 598 | 0.590 |
Why?
|
| Proteins | 2 | 2021 | 1963 | 0.550 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 358 | 0.500 |
Why?
|
| Wilms Tumor | 1 | 2016 | 292 | 0.480 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 98 | 0.470 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 551 | 0.440 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2014 | 221 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3552 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2022 | 6915 | 0.360 |
Why?
|
| alpha-Thalassemia | 1 | 2009 | 11 | 0.350 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2009 | 19 | 0.350 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2009 | 20 | 0.350 |
Why?
|
| Fetal Diseases | 1 | 2009 | 388 | 0.260 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 110 | 0.220 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 3022 | 0.220 |
Why?
|
| Small Molecule Libraries | 2 | 2022 | 169 | 0.220 |
Why?
|
| Contraceptive Agents, Male | 1 | 2022 | 20 | 0.210 |
Why?
|
| Electronics | 1 | 2022 | 58 | 0.210 |
Why?
|
| Methyltransferases | 2 | 2015 | 148 | 0.210 |
Why?
|
| Selenium | 1 | 2022 | 47 | 0.210 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 78 | 0.190 |
Why?
|
| Language Development Disorders | 1 | 2022 | 167 | 0.190 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 184 | 0.190 |
Why?
|
| Child | 9 | 2023 | 29154 | 0.190 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2022 | 197 | 0.180 |
Why?
|
| Aniline Compounds | 2 | 2021 | 177 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2022 | 324 | 0.170 |
Why?
|
| Gene Editing | 1 | 2021 | 216 | 0.170 |
Why?
|
| Pyrazines | 1 | 2021 | 495 | 0.170 |
Why?
|
| Ependymoma | 1 | 2021 | 242 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 521 | 0.160 |
Why?
|
| Cell Survival | 2 | 2021 | 3045 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 413 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3821 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4849 | 0.150 |
Why?
|
| Spiro Compounds | 1 | 2016 | 58 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 363 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 79 | 0.140 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 88 | 0.140 |
Why?
|
| Apoptosis | 3 | 2021 | 7591 | 0.140 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14289 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2016 | 64 | 0.140 |
Why?
|
| Mice | 6 | 2022 | 34495 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 249 | 0.130 |
Why?
|
| Humans | 20 | 2023 | 261506 | 0.130 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7226 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2022 | 1032 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 3343 | 0.120 |
Why?
|
| Mutation | 1 | 2014 | 15179 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.120 |
Why?
|
| Fibrosarcoma | 1 | 2014 | 135 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1399 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 14551 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 507 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.110 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2014 | 109 | 0.110 |
Why?
|
| Animals | 8 | 2022 | 59536 | 0.110 |
Why?
|
| Fever | 1 | 2015 | 497 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8873 | 0.110 |
Why?
|
| Nitriles | 1 | 2017 | 906 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2021 | 9244 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 7548 | 0.100 |
Why?
|
| Indoles | 1 | 2016 | 1009 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 6550 | 0.100 |
Why?
|
| Neutropenia | 1 | 2015 | 968 | 0.100 |
Why?
|
| Structure-Activity Relationship | 3 | 2022 | 931 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2023 | 5270 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2330 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 4053 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2023 | 16273 | 0.090 |
Why?
|
| Chimerism | 1 | 2009 | 63 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2014 | 540 | 0.080 |
Why?
|
| Oncogenes | 2 | 2022 | 673 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2015 | 851 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 4821 | 0.080 |
Why?
|
| Phenotype | 2 | 2022 | 6295 | 0.080 |
Why?
|
| Histones | 1 | 2015 | 1466 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 1879 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 212 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 1062 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8865 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 590 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 769 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 674 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 109 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 211 | 0.060 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 46 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2992 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 245 | 0.050 |
Why?
|
| Neoplasms | 2 | 2021 | 15193 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 76 | 0.050 |
Why?
|
| Adenosine | 2 | 2015 | 289 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2002 | 240 | 0.050 |
Why?
|
| Serotonin | 1 | 2002 | 264 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 434 | 0.050 |
Why?
|
| Protein Domains | 1 | 2022 | 314 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8223 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2015 | 461 | 0.050 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 580 | 0.040 |
Why?
|
| Female | 4 | 2016 | 141928 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2022 | 467 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2016 | 3005 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2017 | 4307 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 665 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 1020 | 0.040 |
Why?
|
| Aorta | 1 | 2002 | 692 | 0.040 |
Why?
|
| Benzamides | 1 | 2023 | 1832 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 783 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 978 | 0.040 |
Why?
|
| Indolizines | 1 | 2016 | 45 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 801 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 63 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 289 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 106 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 21713 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7573 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 1656 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7222 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2022 | 1026 | 0.030 |
Why?
|
| Remission Induction | 1 | 2022 | 3569 | 0.030 |
Why?
|
| S-Adenosylmethionine | 1 | 2015 | 43 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2017 | 11965 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 2693 | 0.030 |
Why?
|
| Infant | 2 | 2022 | 13310 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 597 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5178 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 995 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 12926 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 105 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2012 | 300 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 3536 | 0.030 |
Why?
|
| Catalysis | 1 | 2012 | 250 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2012 | 549 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 303 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 923 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1732 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 1555 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 2049 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 4938 | 0.020 |
Why?
|
| Adolescent | 2 | 2022 | 31252 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 4804 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1818 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 929 | 0.020 |
Why?
|
| United States | 1 | 2023 | 15433 | 0.020 |
Why?
|
| Male | 2 | 2022 | 123000 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 21445 | 0.010 |
Why?
|
| Denervation | 1 | 2002 | 33 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 12873 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 37905 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 1541 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 1338 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 2307 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 2063 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 15862 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 6086 | 0.010 |
Why?
|